- Home
- LRE vs APM Comparison
LRE vs APM Comparison
Compare LRE & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- APM
- Stock Information
- Founded
- LRE 2001
- APM 2010
- Country
- LRE Japan
- APM United Kingdom
- Employees
- LRE N/A
- APM N/A
- Industry
- LRE
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- APM Health Care
- Exchange
- LRE Nasdaq
- APM Nasdaq
- Market Cap
- LRE 20.5M
- APM 18.9M
- IPO Year
- LRE 2023
- APM 2018
- Fundamental
- Price
- LRE $1.56
- APM $1.98
- Analyst Decision
- LRE
- APM
- Analyst Count
- LRE 0
- APM 0
- Target Price
- LRE N/A
- APM N/A
- AVG Volume (30 Days)
- LRE 80.4K
- APM 20.5M
- Earning Date
- LRE 07-30-2015
- APM 04-30-2025
- Dividend Yield
- LRE N/A
- APM N/A
- EPS Growth
- LRE N/A
- APM N/A
- EPS
- LRE N/A
- APM N/A
- Revenue
- LRE $110,330,328.00
- APM N/A
- Revenue This Year
- LRE N/A
- APM N/A
- Revenue Next Year
- LRE N/A
- APM N/A
- P/E Ratio
- LRE N/A
- APM N/A
- Revenue Growth
- LRE 3.92
- APM N/A
- 52 Week Low
- LRE $1.00
- APM $0.46
- 52 Week High
- LRE $2.49
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- LRE 53.48
- APM 52.67
- Support Level
- LRE $1.29
- APM $1.64
- Resistance Level
- LRE $1.44
- APM $2.65
- Average True Range (ATR)
- LRE 0.14
- APM 0.21
- MACD
- LRE 0.01
- APM -0.05
- Stochastic Oscillator
- LRE 91.89
- APM 33.66
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.